Cargando…

Heterogeneity in cardiovascular death or hospitalization for heart failure benefits with flozins is linked to weight

AIMS: Cardiovascular outcome trials with sodium–glucose cotransporter 2 inhibitors (SGLT‐2is) have documented a positive impact on micro‐ and macrovascular complications of type 2 diabetes (T2D). Most analyses suggest that these benefits are independent of achieving metabolic control. This meta‐regr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghosal, Samit, Sinha, Binayak, Mukherjee, Rik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053285/
https://www.ncbi.nlm.nih.gov/pubmed/36707061
http://dx.doi.org/10.1002/ehf2.14296
_version_ 1785015377470685184
author Ghosal, Samit
Sinha, Binayak
Mukherjee, Rik
author_facet Ghosal, Samit
Sinha, Binayak
Mukherjee, Rik
author_sort Ghosal, Samit
collection PubMed
description AIMS: Cardiovascular outcome trials with sodium–glucose cotransporter 2 inhibitors (SGLT‐2is) have documented a positive impact on micro‐ and macrovascular complications of type 2 diabetes (T2D). Most analyses suggest that these benefits are independent of achieving metabolic control. This meta‐regression analysis was undertaken to explore the relationship between metabolic components positively influenced by SGLT‐2is and a reduction in cardiovascular death (CV death) or hospitalization due to heart failure (hHF). METHODS AND RESULTS: A database search was conducted using the Cochrane Library to identify relevant studies. Analysis was conducted using CMA and RStudio (2022.07.1) software. The hazard ratios of the individual studies were used to compute the random effects model mean effect size for CV death or hHF, and the prediction interval was used to identify the uncertainty in the summary treatment effect. Heterogeneity was quantified using Q statistics. A pooled population of 46 969 patients from five studies was included for analysis. The Cochrane risk of bias tool was used to assess the quality of the studies. There was a significant 23% reduction in CV deaths or hHFs in the SGLT‐2i arm compared with the placebo arm [hazard ratio (HR): 0.77, 95% confidence interval (CI) 0.70–0.85]. However, the prediction interval (0.57–1.05) and the Q statistics [8.06 > degrees of freedom (df) of 4] were indicative of uncertainty in the true effect or heterogeneity. Nearly 50% of the variance of the observed effects were related to the true effects (I (2) = 50%). Among the moderators selected, a significant correlation of the outcomes was found with the weight variable (P < 0.01). Weight differential could explain the entire variance in true effect size (R (2) = 1.00) ruling out any sampling error. CONCLUSIONS: The results of this meta‐regression analysis suggest that the beneficial effects of SGLT‐2is in reducing CV deaths and hHFs are related to the weight variable.
format Online
Article
Text
id pubmed-10053285
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-100532852023-03-30 Heterogeneity in cardiovascular death or hospitalization for heart failure benefits with flozins is linked to weight Ghosal, Samit Sinha, Binayak Mukherjee, Rik ESC Heart Fail Original Articles AIMS: Cardiovascular outcome trials with sodium–glucose cotransporter 2 inhibitors (SGLT‐2is) have documented a positive impact on micro‐ and macrovascular complications of type 2 diabetes (T2D). Most analyses suggest that these benefits are independent of achieving metabolic control. This meta‐regression analysis was undertaken to explore the relationship between metabolic components positively influenced by SGLT‐2is and a reduction in cardiovascular death (CV death) or hospitalization due to heart failure (hHF). METHODS AND RESULTS: A database search was conducted using the Cochrane Library to identify relevant studies. Analysis was conducted using CMA and RStudio (2022.07.1) software. The hazard ratios of the individual studies were used to compute the random effects model mean effect size for CV death or hHF, and the prediction interval was used to identify the uncertainty in the summary treatment effect. Heterogeneity was quantified using Q statistics. A pooled population of 46 969 patients from five studies was included for analysis. The Cochrane risk of bias tool was used to assess the quality of the studies. There was a significant 23% reduction in CV deaths or hHFs in the SGLT‐2i arm compared with the placebo arm [hazard ratio (HR): 0.77, 95% confidence interval (CI) 0.70–0.85]. However, the prediction interval (0.57–1.05) and the Q statistics [8.06 > degrees of freedom (df) of 4] were indicative of uncertainty in the true effect or heterogeneity. Nearly 50% of the variance of the observed effects were related to the true effects (I (2) = 50%). Among the moderators selected, a significant correlation of the outcomes was found with the weight variable (P < 0.01). Weight differential could explain the entire variance in true effect size (R (2) = 1.00) ruling out any sampling error. CONCLUSIONS: The results of this meta‐regression analysis suggest that the beneficial effects of SGLT‐2is in reducing CV deaths and hHFs are related to the weight variable. John Wiley and Sons Inc. 2023-01-27 /pmc/articles/PMC10053285/ /pubmed/36707061 http://dx.doi.org/10.1002/ehf2.14296 Text en © 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Ghosal, Samit
Sinha, Binayak
Mukherjee, Rik
Heterogeneity in cardiovascular death or hospitalization for heart failure benefits with flozins is linked to weight
title Heterogeneity in cardiovascular death or hospitalization for heart failure benefits with flozins is linked to weight
title_full Heterogeneity in cardiovascular death or hospitalization for heart failure benefits with flozins is linked to weight
title_fullStr Heterogeneity in cardiovascular death or hospitalization for heart failure benefits with flozins is linked to weight
title_full_unstemmed Heterogeneity in cardiovascular death or hospitalization for heart failure benefits with flozins is linked to weight
title_short Heterogeneity in cardiovascular death or hospitalization for heart failure benefits with flozins is linked to weight
title_sort heterogeneity in cardiovascular death or hospitalization for heart failure benefits with flozins is linked to weight
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053285/
https://www.ncbi.nlm.nih.gov/pubmed/36707061
http://dx.doi.org/10.1002/ehf2.14296
work_keys_str_mv AT ghosalsamit heterogeneityincardiovasculardeathorhospitalizationforheartfailurebenefitswithflozinsislinkedtoweight
AT sinhabinayak heterogeneityincardiovasculardeathorhospitalizationforheartfailurebenefitswithflozinsislinkedtoweight
AT mukherjeerik heterogeneityincardiovasculardeathorhospitalizationforheartfailurebenefitswithflozinsislinkedtoweight